CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity

John F. Imbery, Celina Wiik, Julia Heinzelbecker, Jenny K. Jebsen, Mia K. Dobbing, Nunzio Bottini, Stephanie M. Stanford, Ludvig A. Munthe, Geir E. Tjønnfjord, Anders Tveita, Peter Szodoray, Britt Nakken
{"title":"CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity","authors":"John F. Imbery, Celina Wiik, Julia Heinzelbecker, Jenny K. Jebsen, Mia K. Dobbing, Nunzio Bottini, Stephanie M. Stanford, Ludvig A. Munthe, Geir E. Tjønnfjord, Anders Tveita, Peter Szodoray, Britt Nakken","doi":"10.1016/j.omton.2024.200841","DOIUrl":null,"url":null,"abstract":"Chronic lymphocytic leukemia (CLL) growth is dependent on both B cell receptor (BCR) signaling and signals from microenvironmental T helper (Th) cells. We previously described a mechanism where Th cells enhance BCR signaling and proliferation through CD45 phosphatase activity regulation via galectin-1 and CD43. The CLL negative prognostic indicator CD38 is linked to BCR signaling and proliferation, with its expression induced by Th cells. Here, we explore a link between CD38 and CD45 phosphatase activity regulation using patient-derived material in a Th-CLL cell co-culture model. Results demonstrate CD43 and galectin-1 are co-expressed with CD38, defining proliferative CLL cells with augmented CD45 activity. CD38 enzymatic and receptor inhibition regulated CD43 and galectin-1 expression, CD45 activity populations, and CLL proliferation, while leaving Th cells largely unaffected. Mechanistically, - or (galectin-1)-deficient malignant B cell lines further confirmed CD38-mediated regulation of CD45 activity and BCR signaling through CD43 expression and galectin-1 surface binding, while galectin-1 contributed to CD43/CD45 colocalization. Together, this highlights CD38 as an important regulator of CD45 activity via CD43 and galectin-1, in turn acting as a positive modulator of CLL proliferation. Ultimately, the CD38/CD45 molecular hub could be an important therapeutic target in CLL.","PeriodicalId":519910,"journal":{"name":"Molecular Therapy: Oncology","volume":"43 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy: Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.omton.2024.200841","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic lymphocytic leukemia (CLL) growth is dependent on both B cell receptor (BCR) signaling and signals from microenvironmental T helper (Th) cells. We previously described a mechanism where Th cells enhance BCR signaling and proliferation through CD45 phosphatase activity regulation via galectin-1 and CD43. The CLL negative prognostic indicator CD38 is linked to BCR signaling and proliferation, with its expression induced by Th cells. Here, we explore a link between CD38 and CD45 phosphatase activity regulation using patient-derived material in a Th-CLL cell co-culture model. Results demonstrate CD43 and galectin-1 are co-expressed with CD38, defining proliferative CLL cells with augmented CD45 activity. CD38 enzymatic and receptor inhibition regulated CD43 and galectin-1 expression, CD45 activity populations, and CLL proliferation, while leaving Th cells largely unaffected. Mechanistically, - or (galectin-1)-deficient malignant B cell lines further confirmed CD38-mediated regulation of CD45 activity and BCR signaling through CD43 expression and galectin-1 surface binding, while galectin-1 contributed to CD43/CD45 colocalization. Together, this highlights CD38 as an important regulator of CD45 activity via CD43 and galectin-1, in turn acting as a positive modulator of CLL proliferation. Ultimately, the CD38/CD45 molecular hub could be an important therapeutic target in CLL.
CD38 通过 CD45 磷酸酶活性调节慢性淋巴细胞白血病的增殖
慢性淋巴细胞白血病(CLL)的生长依赖于 B 细胞受体(BCR)信号和来自微环境 T 辅助细胞(Th)的信号。我们以前曾描述过一种机制,即Th细胞通过galectin-1和CD43调控CD45磷酸酶活性,从而增强BCR信号转导和增殖。CLL阴性预后指标CD38与BCR信号转导和增殖有关,其表达由Th细胞诱导。在此,我们利用Th-CLL细胞共培养模型中的患者来源材料,探讨了CD38和CD45磷酸酶活性调节之间的联系。结果表明 CD43 和 galectin-1 与 CD38 共同表达,从而确定了 CD45 活性增强的增殖性 CLL 细胞。CD38 酶抑制剂和受体抑制剂可调节 CD43 和 galectin-1 的表达、CD45 活性群体和 CLL 增殖,而 Th 细胞则基本不受影响。从机制上讲,-或(galectin-1)缺陷的恶性B细胞系进一步证实了CD38通过CD43表达和galectin-1表面结合介导的CD45活性调节和BCR信号转导,而galectin-1有助于CD43/CD45共定位。总之,这凸显了 CD38 通过 CD43 和 galectin-1 成为 CD45 活性的重要调节因子,进而成为 CLL 增殖的积极调节因子。最终,CD38/CD45分子枢纽可能成为CLL的一个重要治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信